Amneal Pharmaceuticals Stock Price, News & Analysis (NYSE:AMRX)

$3.34
+0.19 (+6.03 %)
(As of 09/22/2019 08:25 AM ET)
Today's Range
$3.1025
Now: $3.34
$3.38
50-Day Range
$2.33
MA: $2.88
$3.54
52-Week Range
$2.27
Now: $3.34
$24.35
Volume2.67 million shs
Average Volume1.97 million shs
Market Capitalization$998.96 million
P/E Ratio3.52
Dividend YieldN/A
Beta1.49
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.86 billion
Cash Flow$1.5113 per share
Book Value$3.00 per share

Profitability

Net Income$-169,730,000.00

Miscellaneous

Employees6,000
Market Cap$998.96 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.


Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Monday, August, 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.05. The business had revenue of $404.60 million for the quarter, compared to analysts' expectations of $420.12 million. Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The business's revenue for the quarter was down 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS. View Amneal Pharmaceuticals' Earnings History.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Amneal Pharmaceuticals.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share (EPS) guidance of $0.52-0.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.61.

What price target have analysts set for AMRX?

11 Wall Street analysts have issued 1-year price objectives for Amneal Pharmaceuticals' shares. Their predictions range from $2.50 to $19.00. On average, they anticipate Amneal Pharmaceuticals' share price to reach $9.00 in the next year. This suggests a possible upside of 169.5% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.

What is the consensus analysts' recommendation for Amneal Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.

What are Wall Street analysts saying about Amneal Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (9/10/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Media coverage about AMRX stock has been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Amneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totalling 6,656,500 shares, an increase of 15.7% from the July 31st total of 5,754,100 shares. Based on an average daily volume of 1,950,000 shares, the days-to-cover ratio is currently 3.4 days. Approximately 9.1% of the company's stock are short sold. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Encana (ECA), Amarin (AMRN), Exelixis (EXEL), Micron Technology (MU), Nektar Therapeutics (NKTR), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), ADMA Biologics (ADMA), Cisco Systems (CSCO) and Opko Health (OPK).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.24%), Vanguard Group Inc. (3.26%), BlackRock Inc. (2.14%), Point72 Asset Management L.P. (1.11%), Northern Trust Corp (0.40%) and Charles Schwab Investment Management Inc. (0.24%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Wells Fargo & Company MN, Balyasny Asset Management LLC, Parametric Portfolio Associates LLC, TD Asset Management Inc. and A.R.T. Advisors LLC. View Insider Buying and Selling for Amneal Pharmaceuticals.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Nuveen Asset Management LLC, SG Americas Securities LLC, Vanguard Group Inc., Cubist Systematic Strategies LLC, Invesco Ltd. and Voloridge Investment Management LLC. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $3.34.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $998.96 million and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  281 (Thanks for Voting!)
Underperform Votes:  330 (Thanks for Voting!)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Featured Article: What is a Derivative?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel